BACKGROUND: Antimicrobial resistance data from surveillance networks are frequently do not accurately predict resistance patterns of urinary tract infections at the bedside.
Introduction
Urinary tract infections (UTIs) are very common both in the community and healthcare settings. The most common pathogen isolated is Escherichia coli: it accounts for 70-90% of uncomplicated and 50-60% of recurrent or complicated infections [1, 2] . Appropriate empirical antibiotic treatment of UTIs is important for successful outcome and preventing complications. However, antimicrobial resistance to antibiotics commonly used against E. coli has emerged worldwide and has converted UTIs into infectious diseases challenging to treat [3] [4] [5] .
The recently published US and European guidelines recommend empirical treatment of UTIs based on ongoing surveillance of local resistance rates of uropathogens [6] . However, common surveillance networks provide cumulative resistance rates, which give only a rough estimate of the local resistance situation and may not predict E. coli resistance patterns on different wards of an institution or even on an individual level. Only a few studies have investigated the role of demographic and host-related factors in colonisation or infection with resistant urinary tract pathogens, and these have had inconclusive results [3, [7] [8] [9] [10] [11] .
The aim of our study was to determine bedside-available patient-and institution-related risk factors impacting on antimicrobial resistance of E. coli urine isolates in Switzerland to improve appropriate empirical antibiotic treatment of UTIs.
Materials and methods
The study was approved by the local ethics committee as part of the continuous quality improvement programme.
Study setting and design
The University Hospital Basel is a 865-bed tertiary academic care centre in Switzerland with an average of 38,000 hospital admissions per year and around 90,000 urine samples processed at the Clinical Microbiology Laboratory in the years 2012 to 2015.
For our study, all consecutive urine samples from in-and outpatients collected at the University Hospital Basel from 1 January 2012 until 31 May 2015 with growth of E. coli (≥10 3 colony forming units [CFU]/ml) and antimicrobial susceptibility testing were included. Urine samples came from patients with asymptomatic bacteriuria as well as from patients with UTIs.
Serial urine samples from the same patient within 1 year, samples from patients in the dialysis and haematological outpatient unit, from paediatric patients aged <15 years, samples with polymicrobial flora (>2 pathogens without a dominant microorganism) and specimens from external clinics were excluded from the study.
Urine cultures were performed according to standard laboratory procedures [12] . The antimicrobial susceptibility was tested using Vitek 2 automated system (bioMérieux) or Etest (bioMérieux). Non-susceptible, in the following termed "resistant", was defined as being resistant or intermediate according to EUCAST clinical breakpoints version 2.0-5.0.
Definitions
An outpatient urine sample was defined as a specimen that was collected in one of the various outpatient clinics (emergency room, or internal medicine, surgical, gynaecological or urological outpatient units) or from hospitalised patients when obtained within the first 2 days after admission. The remaining urine samples were considered as inpatient samples.
Hospital units were grouped as follows: (1) medicine -inpatient wards of internal medicine, geriatrics, neurology, oncology, radiooncology; (2) surgery -inpatient wards of all surgical disciplines except gynaecolgy and urology; (3) gynecology -all inpatient gynecological and obstetric wards and the gynecological outpatient unit; (4) intensive care units -medical and surgical intensive care units and intermediate care unit; (5) haematology -inpatient haematology isolation unit; (6) urology -urology in-and outpatient units; (7) outpatient units -all outpatient units such as the emergency room, internal medicine and surgical outpatient units (except gynaecology and urology outpatient units). 
Results
During the study period, 20,789 microorganisms (polymicrobial flora excluded) were detected in 18,413 urine samples from 10,887 patients ( fig. 1) In patients ≥65 years, resistance rates for ciprofloxacin and nitrofurantoin were significantly higher than those in patients <65 years old (OR 1.18, 95% CI 1.12-1.24; p <0.001 and OR 1.21, 95% CI 1.05-1.39; p = 0.03, respectively), whereas resistance rates for amoxicillin (OR 0.93, 95% CI 0.90-0.99; p = 0.012) and cotrimoxazole (OR 0.91, 95% CI 0.86-0.96; p <0.001) were significantly lower. For the other antibiotics, no difference could be found between these age groups.
After results were stratified into 10-year age intervals, antimicrobial resistance to beta-lactam antibiotics, cotrimox- Amoxicillin Amoxicillinclavulanic acid
Piperacillintazobactam
Ceftriaxone Cefepime Meropenem Ciprofloxacin Cotrimoxazole Nitrofurantoin Amikacin Fosfomycin All samples (n/%) n = 5235 n = 5241 n = 5171 n = 5246 n = 5244 n = 5246 n = 5233 n = 5245 n = 5231 n = 5233 n = 5232 n = 5246 Overall, E. coli isolates in urine collected from indwelling catheters showed generally higher resistance rates compared with those taken after single-use catheterisation, midstream urine specimens and urine of unknown origin together. However, these differences were only significant for amoxicillin, ciprofloxacin and cotrimoxazole (table 2  and fig. 1c ).
The antimicrobial susceptibility pattern did not differ significantly between in-and outpatient urine samples, except for ceftriaxone (table 2 and fig. 1d ).
Multivariable analysis was performed to identify independent associations with resistance against the commonly used oral antibiotics amoxicillin-clavulanic acid, ciprofloxacin and cotrimoxazole. Male gender, age ≥65years, indwelling catheters and urine samples from the urological unit were independently associated with resistance to ciprofloxacin (table 3) . Similarly, resistance to cotrimoxazole was significantly associated with male gender, urine from indwelling catheters and sample collection from the urological unit, but age ≥65years was predictive for lower resistance. For amoxicillin-clavulanic acid only male gender was associated with resistance.
Analyses of this kind may be confounded by changes in the overall antibiotic consumption in our institution during the study period. However, consumption (expressed in DDDs per 100 patient-days) in the urological inpatient unit was similar to that of the whole hospital for all antibiotics (55.2 and 52.0, respectively) and for the fluoroquinolones (4.5 and 4. 
Discussion
Antimicrobial susceptibility patterns of E. coli are influenced by many factors and vary considerably in different parts of the world [3] [4] [5] 13] . Cumulative resistance data from national and local antimicrobial surveillance networks are used to develop local prescribing guidelines, but they do not take individual patient factors into account.
Our study did not intend to search for new risk factors by using exhaustive clinical and microbiological data, but to find readily available bedside clinical data to optimise empirical antimicrobial therapy for suspected UTI. In our study we could demonstrate that simple demographic and patient characteristics further helped in predicting antimicrobial resistance of urinary tract E. coli isolates. For most of the analysed antibiotics, male, middle-aged and urological patients showed higher resistance rates, whereas indwelling urinary tract catheters and hospitalisation seemed to have worsening influence on antimicrobial resistance. We found overall high resistance rates for the commonly used oral antibiotics, such as amoxicillin (43.2%), cotrimoxazole (24.5%), ciprofloxacin (17.4%) and amoxicillinclavulanic acid (15.5%), whereas resistance remained low for nitrofurantoin and fosfomycin (≤1.5%).
The high rates of resistance to ciprofloxacin (17.4%) and cotrimoxazole (24.5%), two of the oral antibiotics most commonly prescribed to treat UTIs, are of particular concern since they exceeded the IDSA cut-offs of 10 and 20%, respectively [6], above which empirical use of fluoroquinolones and cotrimoxazole in the treatment of UTIs is no longer recommended. For both antibiotics we observed a steady increase of resistant E. coli urine isolates in our institution from 2007 up to the current study period of 2012 to 2015, from 15.9 to 17.4% for ciprofloxacin and 21.3 to 24.5% for cotrimoxazole [9] . The increasing fluoroquinolone resistance in urinary tract E. coli isolates has been described in many reports and is explained by their widespread use [14] [15] [16] . Interestingly, at our institution, including the urological unit, fluoroquinolone consumption is rather low and has even decreased from 6.4 DDD/ 100 patient-days in 2008 [9] to 4.5 DDD/100 patient-days in 2012-2015. On a national level, overall antibiotic use in Switzerland is low compared with other European countries [17] ; however, fluoroquinolone prescription, particularly in the outpatient setting including urological patients, is very high at 20.1% [18] of all antibiotics compared with an average of 7.3% in the other European countries [19] . The widespread use of fluoroquinolones in the outpatient setting may explain the comparable resistance rates in inand outpatients [20, 21] in our study as well as in the Swiss national antimicrobial resistance surveillance database ANRESIS [22] 2012 to 2014.
Various risk factors for antimicrobial resistance of urinary tract E. coli isolates have been described, but remain to some extent controversial. Advanced age, male sex, nosocomial UTIs [20, 21, [23] [24] [25] , an indwelling urinary tract catheter and specimens from urological patients [26, 27] have been described as associated with resistance mainly to fluroquinolones [3, [7] [8] [9] [10] [14] [28, 29] .
In our study, male and urological patients, and to a lesser extent patients with indwelling catheters, were independent predictors for ciprofloxacin and cotrimoxazole resistance. Remarkably, >30% of the E. coli from urological patients were resistant to ciprofloxacin and cotrimoxazole. A high resistance rate in urological patients was also described in other studies [26, 27, 30, 31] . Explanations might be the frequent use of fluoroquinolones for "prolonged" antibiotic prophylaxis in transurethral resection of the prostate and other urological procedures, and the treatment of UTIs, particularaly in males who may receive repeated and prolonged fluorochinolone therapy cycles for susupected prostatitis [31] . Inadequate tissue penetration of the antimicrobial agent with subinhibitory minimal inhibitory concentration (MIC) effects and prolonged therapy may predispose to the selection of more resistant microorganisms in male patients [7, 10, 30, [32] [33] [34] .
Interestingly, advanced age ≥65 year was associated with higher E. coli resistance to ciprofloxacin, whereas for cotrimoxazole resistance rates decreased in eldery patients. These resistance trends for cotrimoxazole and ciprofloxacin were already described at our institution in 2007 [9] . Of note, a reversing resistance trend could also be observed for the beta-lactam antibiotics in patients ≥80 years. No age dependence was found for antibiotics with a very low resistance rate, such as meropenem, amikacin, fosfomycin and nitrofurantoin. Our observation is in contrast to many other studies in which age was associated with higher resistance [14, 28] ; however, these studies usually did not evaluate the resistance profile in very eldery patient owing to the decrease sample size with increasing age.
There are limitations of the study that should be mentioned. First, it was a single centre study at a tertiary care hospital in Switzerland. Hospital and laboratory based surveillance data of susceptibility patterns probably overestimate the antibiotic resistance rates, since clinicians may treat uncomplicated UTIs empirically in the outpatient setting without sending a urine sample to the laboratory. Cultures are only performed if the patient fails to respond to treatment, has recurrent episodes of UTI or has complicated UTI [35, 36] .
Second, the retrospective design precluded collecting standardised clinical information on previous antibiotic treatment, previous hospitalisations, catheter dwelling time or whether urine samples came from patients with asymptomatic bacteriuria, UTIs or even prostatitis. However, some studies have found that the E. coli antimicrobial susceptibility profile does not seem to differ greatly between patients with UTI and patients with colonisation only [9, 10, 15, 20] . In addition, the definition and clinical diagnosis of a UTI is not clear cut, but microbiology results are unambiguous.
Third, misclassification may have influenced the results, but because of the large sample size of over 5000 consecutive samples may not be sufficient to change the results generated.
Strengths of our study are the large sample size, use of only one isolate per patient per year to avoid selection bias of more resistant E. coli, the very low loss of data from the samples and the use of simple bedside clinical data.
In conclusion, using readily available bedside data from patients and wards can improve the choice of appropriate antimicrobial therapy in patients with suspected UTI, in addition to the annual reports of the microbiology laboratory on antimicrobial resistance of pathogens isolated from urine.
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